167 related articles for article (PubMed ID: 28977163)
21. Neuroendocrine Carcinoma as a Cause of Humoral Hypercalcemia of Malignancy: A Case of a Patient With Elevated Parathyroid Hormone-Related Protein.
Christensen BR; Rendo MJ; Beeler BW; Huddleston BJ; Fenderson JL
Cureus; 2022 Mar; 14(3):e23398. PubMed ID: 35481321
[TBL] [Abstract][Full Text] [Related]
22. Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a pancreatic neuro-endocrine tumor: a case report.
Haemels M; Delaunoit T; Van Laere K; Van Cutsem E; Verslype C; Deroose CM
BMC Gastroenterol; 2020 Oct; 20(1):324. PubMed ID: 33008295
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour.
Shea YF; Chiu WY; Mok MY; Hung IF; Yau CC
J Clin Pharm Ther; 2013 Aug; 38(4):327-9. PubMed ID: 23586819
[TBL] [Abstract][Full Text] [Related]
25. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet.
Apostolou T; Damianou L; Kotsiev V; Drakopoulos S; Hadjiconstantinou V
Clin Nephrol; 2006 May; 65(5):374-7. PubMed ID: 16724661
[TBL] [Abstract][Full Text] [Related]
26. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
[TBL] [Abstract][Full Text] [Related]
27. Sunitinib and everolimus in pancreatic neuroendocrine tumors.
Procopio G; Pusceddu S; Buzzoni R
Tumori; 2012; 98(3):394. PubMed ID: 22825518
[No Abstract] [Full Text] [Related]
28. Sunitinib for advanced pancreatic neuroendocrine tumors.
Hubner RA; Valle JW
Expert Rev Anticancer Ther; 2011 Dec; 11(12):1817-27. PubMed ID: 22117148
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib Efficacy in Patients with Advanced pNET in Clinical Practice.
Lahner H; Rinke A; Unger N; Poeppel TD; Kühl H; Lehmann N; Führer D
Horm Metab Res; 2016 Sep; 48(9):575-80. PubMed ID: 27101094
[TBL] [Abstract][Full Text] [Related]
30. Persistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl.
Henrich LM; Rogol AD; D'Amour P; Levine MA; Hanks JB; Bruns DE
Clin Chem; 2006 Dec; 52(12):2286-93. PubMed ID: 17105782
[TBL] [Abstract][Full Text] [Related]
31. Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma).
Bourcier ME; Vinik AI
Pancreas; 2013 Mar; 42(2):348-52. PubMed ID: 23407483
[TBL] [Abstract][Full Text] [Related]
32. Cinacalcet for hypercalcemia caused by pulmonary squamous cell carcinoma producing parathyroid hormone-related Peptide.
Bech A; Smolders K; Telting D; de Boer H
Case Rep Oncol; 2012 Jan; 5(1):1-8. PubMed ID: 22379470
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
Bisht S; Feldmann G; Brossart P
Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):777-88. PubMed ID: 23590356
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
Zavvos V; Fyssa L; Papasotiriou M; Papachristou E; Ntrinias T; Savvidaki E; Goumenos DS
Exp Clin Transplant; 2018 Jun; 16(3):287-293. PubMed ID: 29108515
[TBL] [Abstract][Full Text] [Related]
35. Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors.
Lee L; Ito T; Igarashi H; Miki M; Fujimori N; Kawabe K; Jensen RT; Ogawa Y
Cancer Chemother Pharmacol; 2018 Jan; 81(1):163-169. PubMed ID: 29164297
[TBL] [Abstract][Full Text] [Related]
36. Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism.
Wiedmer T; Blank A; Pantasis S; Normand L; Bill R; Krebs P; Tschan MP; Marinoni I; Perren A
Mol Cancer Ther; 2017 Nov; 16(11):2502-2515. PubMed ID: 28729403
[TBL] [Abstract][Full Text] [Related]
37. Advances in pancreatic neuroendocrine tumor treatment.
Mir O; Coriat R; Goldwasser F
N Engl J Med; 2011 May; 364(19):1871; author reply 1873-4. PubMed ID: 21561358
[No Abstract] [Full Text] [Related]
38. Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes.
Huda MS; Amiel SA; Ross P; Aylwin SJ
Diabetes Care; 2014; 37(5):e87-8. PubMed ID: 24757248
[No Abstract] [Full Text] [Related]
39. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
Mateo J; Heymach JV; Zurita AJ
Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
[TBL] [Abstract][Full Text] [Related]
40. Cinacalcet increases renal calcium excretion in PTHrP-mediated hypercalcemia: a case report.
Faiq S; Lavelle K; Hu T; Shoback D; Ku G
BMC Endocr Disord; 2023 Jun; 23(1):133. PubMed ID: 37328745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
